Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
Chen
Feng
F
Li
Lizhen
L
Ma
Daoxin
D
Yan
Shuxin
S
Sun
Jianzhi
J
Zhang
Maohong
M
Ji
Chunyan
C
Hou
Ming
M
D000328:Adult; D001549:Benzamides; D020732:Cytogenetic Analysis; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000188:drug therapy; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods
D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C047330:N-methylisoindigotin; C027185:indirubin